Despite several therapeutic advances over the past decade, multiple myeloma (MM)
remains largely incurable, indicating a need for new treatment approaches. Chimeric …

Multiple myeloma (MM) remains an incurable hematologic malignancy, despite the
development of numerous innovative therapies during the past two decades …

Cilta-cel, a BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma,
was approved in USA on 28 February 2022, for patients with relapsed or refractory disease …

Despite the recent introduction of new therapies for multiple myeloma (MM), it remains an
incurable disease. As MM progresses, patients experience cycles of relapse and remission …

Cancer associated thrombosis (CAT) is associated with significant morbidity and mortality,
highlighting an unmet clinical need to improve understanding of the pathophysiology of …

Simple Summary The evolving data from trials assessing novel combinations as a part of the
frontline and relapse treatment in transplant and non-transplant candidates have markedly …

In the ELOQUENT-3 trial, the combination of elotuzumab, pomalidomide and
dexamethasone (EloPd) proved to have a superior clinical benefit over pomalidomide and …

Multiple myeloma (MM) is the second‐ranking malignancy in hematological tumors. The
pathogenesis of MM is complex with high heterogeneity, and the development of the …

Abstract N6-methyladenosine (m 6 A) is the most prevalent modification to RNA in higher
eukaryotes. ALKBH5 is an RNA demethylase that impacts RNA export and metabolism, and …

The increase in the number of therapeutic alternatives for both newly diagnosed and
relapsed/refractory multiple myeloma (RRMM) patients has widened the clinical scenario …